{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/gord-in-children/","result":{"data":{"firstChapter":{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field a897b611-a204-40da-b4d1-fec2d4971d34 --><h1>GORD in children: Summary</h1><!-- end field a897b611-a204-40da-b4d1-fec2d4971d34 -->","htmlStringContent":"<!-- begin item 1803d75a-f61a-40a2-aa2d-54cf75582f2c --><!-- begin field 32a029b9-eb45-4479-865e-4f5c746668d7 --><ul><li>Gastro-oesophageal reflux (GOR) is the passage of gastric contents into the oesophagus. It is considered physiological in infants when symptoms are absent or not troublesome.</li><li>Gastro-oesophageal reflux disease (GORD) in children is the presence of troublesome symptoms (for example discomfort or pain) or complications (such as oesophagitis or pulmonary aspiration) arising from GOR. Risk factors include:<ul><li>Premature birth.</li><li>Parental history of heartburn or acid regurgitation.</li><li>Obesity.</li><li>Hiatus hernia.</li><li>History of congenital diaphragmatic hernia (repaired) or congenital oesophageal atresia (repaired).</li><li>Neurodisability (such as cerebral palsy).</li></ul></li><li>Regurgitation is the voluntary and involuntary movement of part or all of the stomach contents up the oesophagus at least as far as the mouth and often emerging from the mouth. In infants (younger than 1 year of age), it may be considered entirely normal. In older children, it may be a symptom of GOR or GORD.</li><li>Regurgitation and GORD usually begin before the age of 8 weeks and resolve in 90% of infants before they are 1 year of age.</li><li>GORD should be suspected in infants presenting with regurgitation and one or more of the following:<ul><li>Distressed behaviour shown, for example, by excessive crying, crying while feeding, and adopting unusual neck postures.</li><li>Hoarseness and/or chronic cough.</li><li>A single episode of pneumonia.</li><li>Unexplained feeding difficulties.</li><li>Faltering growth.</li></ul></li><li>GORD should be suspected in children over 1 year who present with heartburn, retrosternal pain, or epigastric pain.</li><li>Same-day admission should be arranged if the child has:<ul><li>Haematemesis (not caused by swallowed blood from a nosebleed or ingested from a cracked maternal nipple).</li><li>Melaena.</li><li>Dysphagia.</li></ul></li><li>Specialist assessment by a paediatrician or paediatric gastroenterologist should be arranged if there is:<ul><li>An uncertain diagnosis or 'red flag' symptoms which suggest a more serious condition.</li><li>Persistent faltering growth associated with regurgitation.</li><li>Suspected complications, such as recurrent aspiration pneumonia, or unexplained apnoeas.</li></ul></li><li>For children who have frequent regurgitation only, parents and carers should be reassured that symptoms are very likely to improve over time.</li><li>For breastfed infants with suspected GORD, a 1–2 week trial of Gaviscon<sup>® </sup>Infant may be considered.</li><li>For formula-fed infants with suspected GORD, a sequential 1–2 week trial of each of the following options (in this order) may be considered: reduction of the volume of feeds, more frequent feeds, thickened feeds (for example Instant Carobel<sup>®</sup>), and Gaviscon<sup>® </sup>Infant.</li><li>For breastfed and formula-fed infants:<ul><li>If treatment with Gaviscon<sup>® </sup>Infant is successful, this may be continued. Treatment should be stopped every 2 weeks to see if symptoms improve and treatment can stopped.</li><li>If treatment with Gaviscon<sup>® </sup>Infant is not successful, a 4–week trial of omeprazole or ranitidine may be considered.</li><li>If symptoms still persist, the child should be referred for specialist assessment.</li></ul></li><li>For children aged 1–2 years of age with suspected GORD, a 4–week trial of omeprazole or ranitidine may be considered.<ul><li>If symptoms still persist, the child should be referred for specialist assessment.</li></ul></li></ul><!-- end field 32a029b9-eb45-4479-865e-4f5c746668d7 --><!-- end item 1803d75a-f61a-40a2-aa2d-54cf75582f2c -->","topic":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b","topicId":"82055e52-e2bf-4f1f-b8dd-b6cfff4b5cba","topicName":"GORD in children","slug":"gord-in-children","aliases":[],"chapters":[{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5c4344fa-cc04-5c8a-8525-0117f05a2a3d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes"},{"id":"76aa1188-2e33-55c6-ba4c-d13b6c09db53","slug":"update","fullItemName":"Update"}]},{"id":"939fae21-c502-5912-ad61-afb229a9fac5","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"23c2943f-6ecf-5571-a559-9818348552ba","slug":"goals","fullItemName":"Goals"},{"id":"caee2b08-a4c2-5fa3-8d43-130a043b68d9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5fb28217-0443-5bfa-a971-4909a5a6c93b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"72771ba0-2707-5c43-b059-6d539cc568df","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"33debdff-0f33-531f-b7c3-a3123aa752ac","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b53e0cd-2b10-5e6f-99ad-e832ae9dde2e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0534b6c6-d8fb-5482-910c-3890eccd28a1","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"b0622c3b-0b7d-5e06-ac6e-b48f44307885","slug":"definition","fullItemName":"Definition"},{"id":"6dc898dd-dd38-5627-be60-ce0f218fcc6f","slug":"causes","fullItemName":"Causes"},{"id":"71b6272e-eb35-5e68-8449-c464d77d7563","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"844a2a73-bae8-5ae2-a218-4de702392498","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7924f80b-3369-54d7-a800-9a0bb22a0242","slug":"complications","fullItemName":"Complications"},{"id":"6ef64f28-7f65-5aaa-8e40-c5ed7f3ead77","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1bff5828-94a1-5984-8ed1-8cde69104288","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"fd58f48a-9a7b-50dd-9c0e-d1c4826f6326","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"4ab712ac-c731-5386-8b93-5afa98f37717","slug":"assessment","fullItemName":"Assessment"},{"id":"5e9aff96-e1cf-58e7-9de4-ffdfa742df08","slug":"differential-diagnosis-red-flag-features","fullItemName":"Differential diagnosis/'red flag' features"}]},{"id":"9ac089f7-44bb-5da5-87a5-a065775dcea0","slug":"management","fullItemName":"Management","subChapters":[{"id":"cfa333ea-866c-555f-8a74-08b659ba92cb","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant"},{"id":"0f6b46fc-04ae-528e-8a4f-182488436dd7","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"033a9c06-1742-5548-9885-53d54c7cc3b0","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"558cd112-f11b-5b2e-a9a9-80f699b1dee5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"9f5b615b-0570-5ba7-8d7a-d4cc5a4dd033","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"30b65237-637c-50a8-90fe-3c945c1a3ee1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45d4b60b-a070-544b-9f14-bee3b54e7f3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58c86f1d-bcc1-59b5-90c0-4a4c75374532","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0691004e-29d1-5b9f-b06e-90eeba4ce3f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7490205e-5357-534e-bf5f-2f2aad729683","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b","topicId":"82055e52-e2bf-4f1f-b8dd-b6cfff4b5cba","topicName":"GORD in children","slug":"gord-in-children","aliases":[],"topicSummary":"Gastro-oesophageal reflux disease (GORD) in children is the presence of troublesome symptoms (for example, discomfort or pain)","lastRevised":"Last revised in September 2020","nextPlannedReviewBy":"2024-02-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-02","nextPlannedReviewByDisplay":"February 2024","specialities":[{"id":"e9e3ea2b-52b8-5242-bc9d-24052ea8647a","name":"Child health","slug":"child-health"},{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"}],"chapters":[{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5c4344fa-cc04-5c8a-8525-0117f05a2a3d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes"},{"id":"76aa1188-2e33-55c6-ba4c-d13b6c09db53","slug":"update","fullItemName":"Update"}]},{"id":"939fae21-c502-5912-ad61-afb229a9fac5","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"23c2943f-6ecf-5571-a559-9818348552ba","slug":"goals","fullItemName":"Goals"},{"id":"caee2b08-a4c2-5fa3-8d43-130a043b68d9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5fb28217-0443-5bfa-a971-4909a5a6c93b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"72771ba0-2707-5c43-b059-6d539cc568df","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"33debdff-0f33-531f-b7c3-a3123aa752ac","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b53e0cd-2b10-5e6f-99ad-e832ae9dde2e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0534b6c6-d8fb-5482-910c-3890eccd28a1","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"b0622c3b-0b7d-5e06-ac6e-b48f44307885","slug":"definition","fullItemName":"Definition"},{"id":"6dc898dd-dd38-5627-be60-ce0f218fcc6f","slug":"causes","fullItemName":"Causes"},{"id":"71b6272e-eb35-5e68-8449-c464d77d7563","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"844a2a73-bae8-5ae2-a218-4de702392498","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7924f80b-3369-54d7-a800-9a0bb22a0242","slug":"complications","fullItemName":"Complications"},{"id":"6ef64f28-7f65-5aaa-8e40-c5ed7f3ead77","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1bff5828-94a1-5984-8ed1-8cde69104288","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"fd58f48a-9a7b-50dd-9c0e-d1c4826f6326","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"4ab712ac-c731-5386-8b93-5afa98f37717","slug":"assessment","fullItemName":"Assessment"},{"id":"5e9aff96-e1cf-58e7-9de4-ffdfa742df08","slug":"differential-diagnosis-red-flag-features","fullItemName":"Differential diagnosis/'red flag' features"}]},{"id":"9ac089f7-44bb-5da5-87a5-a065775dcea0","slug":"management","fullItemName":"Management","subChapters":[{"id":"cfa333ea-866c-555f-8a74-08b659ba92cb","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant"},{"id":"0f6b46fc-04ae-528e-8a4f-182488436dd7","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"033a9c06-1742-5548-9885-53d54c7cc3b0","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"558cd112-f11b-5b2e-a9a9-80f699b1dee5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"9f5b615b-0570-5ba7-8d7a-d4cc5a4dd033","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"30b65237-637c-50a8-90fe-3c945c1a3ee1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45d4b60b-a070-544b-9f14-bee3b54e7f3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58c86f1d-bcc1-59b5-90c0-4a4c75374532","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0691004e-29d1-5b9f-b06e-90eeba4ce3f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7490205e-5357-534e-bf5f-2f2aad729683","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b"}},"staticQueryHashes":["3666801979"]}